ResMed stock steadies as investors weigh obesity drug impact and solid earnings base
Published on 07/20/2026 at 10:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
ResMed Inc. (ISIN US7611521078) is a leading global supplier of equipment and software for sleep apnea and respiratory care, and ResMed stock sits at the intersection of strong underlying demand and ongoing debate about how new obesity drugs may affect its growth trajectory. In its fiscal year ended 30 June 2023, ResMed reported double digit revenue growth and healthy margins, providing a solid fundamental base for investors to analyze even as the discussion about obesity therapies continues to evolve.
Revenue up double digits in fiscal 2023
In fiscal 2023, ResMed generated revenue of approximately $4.2 billion, up around 18% from roughly $3.6 billion in fiscal 2022, as demand for its devices and cloud software remained robust across key regions. This year on year increase reflected both higher volumes in sleep and respiratory care and ongoing expansion in its digital health ecosystem, underlining that the company has managed to grow even in a constrained supply environment. Over the same fiscal period, net income reached around $900 million compared with about $780 million a year earlier, indicating that profit growth lagged but broadly tracked the top line expansion.
Operating profitability has been supported by scale but moderated by input cost inflation and supply chain adjustments. ResMed’s gross margin in fiscal 2023 stood near the mid?fifty percent range, compared with a figure in the high?fifty percent area in fiscal 2022, suggesting a modest compression of several percentage points as component costs and logistics weighed on profitability. For investors, the margin trend matters because it frames how much of future revenue growth can translate into earnings per share.
Quarterly results show EPS growth and comparison
In one of the most recent reported quarters, ResMed achieved quarterly revenue of roughly $1.1 billion, representing an increase of about 20% when compared with the same quarter a year earlier where revenue was near $0.9 billion. That quarterly comparison is a concrete signal that demand remained strong across its device and SaaS offerings, and it reinforces the picture of double digit growth at both annual and quarterly levels. Within that quarter, adjusted earnings per share were around $1.80 versus approximately $1.60 in the prior year quarter, a gain of about 12.5% that shows earnings still expanding, though at a slower pace than revenue.
Analysts following ResMed have highlighted that its earnings performance has generally aligned with or only modestly missed consensus expectations in recent periods, as higher costs offset some of the top line strength. In broad terms, consensus has expected mid?teens revenue growth and low double digit EPS growth, and the company’s reported numbers have largely matched that profile. The resulting narrative for ResMed stock is that it combines solid growth with manageable margin pressure, rather than representing a severe earnings downside story.
Product mix and market relevance in sleep and COPD
ResMed’s core business revolves around devices and accompanying software for the treatment of obstructive sleep apnea and chronic obstructive pulmonary disease, including positive airway pressure masks and flow generators as well as monitoring solutions and cloud connectivity. The company estimates that hundreds of millions of people globally suffer from sleep apnea or related conditions, yet a relatively small percentage have been accurately diagnosed and treated, which creates a long runway for customer adoption. A meaningful portion of ResMed’s revenue is tied to recurring mask and supply sales, hinting at a durable revenue stream beyond initial device shipments.
In addition, ResMed has built a growing segment of cloud?based software services for healthcare providers, out?of?hospital care, and home medical equipment management. These software and SaaS offerings have reported segment revenue growth in the double digit percentage range, with some quarters showing growth of 20% or more against the prior year, and they tend to carry higher margins than hardware. For ResMed stock, the continuation of this mix shift toward software and data services is important because it can support margin resilience even if device pricing comes under pressure.
Obesity drug debate and long term demand
An important part of the current narrative around ResMed stock is the market’s focus on obesity drugs, including GLP?1 therapies, and how they might influence sleep apnea prevalence and device demand over time. Some investors fear that widespread adoption of obesity treatments could reduce the incidence of sleep apnea, which often correlates with higher body weight, thereby limiting long term growth for device makers. Others argue that such an impact would be gradual, uncertain, and offset by the large existing pool of undiagnosed patients and non?obesity related drivers of respiratory conditions.
From a fundamental perspective, ResMed’s current earnings and revenue metrics indicate that demand is still rising, not shrinking, even as early data on obesity drugs emerges. The company’s double digit revenue growth in fiscal 2023 and in recent quarters suggests that, so far, obesity therapies have not materially altered its sales trajectory. Investors therefore tend to view the obesity drug impact as a medium to long term scenario that needs close monitoring rather than as an immediate shock to ResMed’s financials.
Cash generation, balance sheet, and dividends
ResMed has historically generated significant operating cash flow thanks to its profitable and relatively asset light business model. In fiscal 2023, operating cash flow was around $1.0 billion, compared with approximately $900 million in fiscal 2022, marking a year on year increase of roughly 11%. This cash generation has enabled the company to invest in research and development, production capacity, and acquisitions in software and home care services while still maintaining a strong balance sheet.
The company’s net debt position remains moderate relative to EBITDA, and ResMed has continued to return capital to shareholders through a regular dividend. The annual dividend payout is measured in the hundreds of millions of dollars, and dividend per share has shown gradual increases over time, though at a measured pace compared with earnings growth. For ResMed stock, the presence of a stable dividend supported by rising cash flow provides an additional layer of investor appeal, particularly for long term holders seeking both growth and income.
Regional trends and supply chain normalization
ResMed’s revenue is geographically diversified across the Americas, Europe, and Asia Pacific, and each region has contributed to the overall growth in fiscal 2023 and recent quarters. The Americas region has remained the largest contributor, with revenue growth in the mid?teens percent range year on year, driven by continued demand for sleep and respiratory care devices and strong adoption of software solutions. Europe and Asia Pacific have posted similar or slightly lower growth rates, often in the high single digit to low double digit range, reflecting varying reimbursement environments and levels of awareness about sleep disorders.
Supply chain challenges and component shortages that affected the broader medical device industry have begun to ease, enabling ResMed to better meet demand and reduce order backlogs. As supply has normalized, the company has had more flexibility to focus on product innovation and efficiency rather than purely on securing parts. This normalization also has implications for margins, as freight and spot procurement costs tend to decline when supply chains stabilize.
Digital health ecosystem and data analytics
Beyond hardware, ResMed continues to invest in its digital health ecosystem, including cloud platforms that track patient adherence, provide remote monitoring, and integrate with provider workflows. These systems support a data?rich environment where clinicians can adjust therapy and patients can engage more actively with their treatment. Revenue from SaaS and digital health offerings has grown at rates above the corporate average in several recent periods, often in the twenty percent range year on year, making this a key strategic focus.
For investors in ResMed stock, the digital health strategy matters because it can deepen customer relationships, increase switching costs, and produce recurring revenue streams that extend beyond the sale of a device. Data analytics and integration capabilities also position ResMed to respond to changes in healthcare policy, payer expectations, and competitive dynamics more quickly than a pure hardware manufacturer might.
Industry competition and innovation cycle
ResMed operates in a competitive field that includes other manufacturers of sleep and respiratory devices, as well as emerging digital health platforms. The company’s history of innovation in mask design, device comfort, and connectivity has helped it maintain and grow market share. It invests a significant portion of its revenue in research and development, with R&D expenses running in the mid single digit percent of sales, sometimes higher when new platform investments are prioritized.
The innovation cycle for sleep and respiratory care devices involves incremental improvements, regulatory approvals, and clinical evidence. ResMed’s ability to introduce new generations of devices and software that improve patient adherence and outcomes is crucial for sustaining its growth profile. Investors monitor pipeline signals, regulatory filings, and clinical data to gauge how well the company is positioned relative to peers.
Representative product line in masks and devices
One of ResMed’s representative product families is its line of positive airway pressure masks and flow generators used in home treatment of obstructive sleep apnea. These products focus on comfort, noise reduction, and ease of use, and they are closely integrated with the company’s cloud connectivity solutions. Device sales often generate recurring revenue from replacement masks and accessories, supporting a durable revenue base.
ResMed stock and market valuation context
ResMed stock trades on the Nasdaq exchange and is part of the broader medical technology and health care equipment sector. The company’s market capitalization is measured in the tens of billions of dollars, reflecting investor expectations for continued growth in sleep and respiratory care and digital health. Shares have experienced periods of volatility as the market reacts to new information about obesity drugs, earnings results, and sector sentiment, but the underlying financial metrics show a company that continues to grow revenue and earnings.
ResMed stock key data
- Company: ResMed Inc.
- ISIN: US7611521078
- Ticker: NASDAQ: RMD
- Trading venue: Nasdaq
- Sector / Industry: Health Care Equipment & Supplies
- Index membership: S&P 500
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
